Epoetin alfa biosimilar - PanGen Biotech
Alternative Names: Erysaa; PDA 10Latest Information Update: 28 Nov 2022
At a glance
- Originator PanGen Biotech
- Developer Duopharma; PanGen Biotech
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
Most Recent Events
- 28 Nov 2022 Registered for Anaemia in South Korea (IV) prior to November 2022 (PanGen Biotech pipeline, November 2022).
- 21 Oct 2020 Preregistration for Anaemia in South Korea (IV) (PanGen Biotech website, October 2020)
- 15 Feb 2017 Duopharma completes a phase III trial in Anaemia in Malaysia and South Korea